APRE Stock Summary and Trading Ideas (Aprea Therapeutics | NASDAQ:APRE)

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Aprea Therapeutics trades on the NASDAQ stock market under the symbol APRE.

As of July 17, 2025, APRE stock price climbed to $1.70 with 31,400 million shares trading.

APRE has a beta of 1.67, meaning it tends to be more sensitive to market movements. APRE has a correlation of 0.13 to the broad based SPY ETF.

APRE has a market cap of $9.40 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, APRE traded as high as $25.80 and as low as $.47.

The top ETF exchange traded funds that APRE belongs to (by Net Assets): VTI, VXF, DFAT.

APRE has underperformed the market in the last year with a price return of -57.4% while the SPY ETF gained +12.5%. APRE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +10.6% and 0.0%, respectively, while the SPY returned +19.8% and +1.3%, respectively.

APRE support price is $1.54 and resistance is $1.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APRE shares will trade within this expected range on the day.